Ospemifene
Also known as: FC-1271a, Osphena
Classification
Serm
Regulatory Status
FDA-approved
Sources
2
Review
n/a
Overview
Ospemifene is a tissue-selective estrogen agonist/antagonist (SERM) with estrogen-like effects on vaginal epithelium and estrogenic activity in endometrium; breast-tissue effect is not fully characterized mechanistically on the label summary used here.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
Benefits
People look up ospemifene (Osphena) as an oral SERM prescription for moderate to severe dyspareunia and vaginal dryness from menopause-related vulvar and vaginal atrophy.
Interactions & cautions
Drug interactions
estrogens and strong CYP3A4/CYP2C9 modulators (label-dependent) — OSPHENA labeling describes drug-interaction considerations via CYP pathways and advises against concomitant estrogens in typical use. (review)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw